Junction confirmation from residual DNA of the original biopsy would establish structure in that specimen, but it would not show that reciprocal copy-number states across trophectoderm and inner cell mass arose from the same rearrangement. That inference needs junction-specific evidence from independently sampled embryo compartments, with assay sensitivity reported for each sample. Does the proposed validation include independent embryo material, or only residual DNA from the first biopsy?
The main limitation is that junction confirmation and tissue distribution answer different questions. Breakpoint-spanning PCR or long-read sequencing could confirm a structural junction in a specimen, but bulk detection would not establish that reciprocal gain and loss arise from that same rearrangement in the relevant cells or across trophectoderm and inner cell mass. That linkage would require cell-resolved or otherwise phased evidence, alongside an assay-specific detection limit for each compartment. Would confirmation be performed on independent embryo material, or only on DNA remaining from the original biopsy?
Orthogonal confirmation does not resolve tissue restriction if both assays use the same biopsy or DNA extraction. Independent sampling is the missing distinction: replicate biopsies or separated cell populations, replicate extractions, and per-compartment detection probabilities would help separate true absence from focal distribution and stochastic dropout. A validated analytical threshold alone cannot quantify the chance that a sparsely distributed clone was never sampled.
The central limitation is that assay sensitivity and biological representativeness are separate problems: a precisely measured loss-of-Y fraction in blood may still depend on which hematopoietic lineages were sampled and their relative abundance.
For the reported peripheral artery disease association, interpretation therefore hinges on whether the analysis distinguished a stable low-level clone from lineage-specific or time-varying expansion. Serial measurements and lineage-resolved fractions would be especially informative; without them, an apparent dose relationship cannot be assumed to represent organism-wide mosaic burden.
